[半乳糖基转移酶同工酶II（GT-II）作为卵巢癌尤其是透明细胞癌的新型肿瘤标志物]
[Galactosyltransferase isozyme II (GT-II) as a new tumor marker for ovarian cancers--especially for clear cell carcinoma].
作者信息
Nozawa S, Kiguchi K, Yajima M, Udagawa Y, Sakuma T, Iizuka R, Narisawa S, Sakayori M
机构信息
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo.
出版信息
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Sep;41(9):1341-7.
Serum levels of galactosyltransferase (GT) and its isozyme (GT-II), which transfers galactose from UDP-galactose to N-acetylglucosamine etc., in gynecologic malignancies, were assayed. GT activity was assayed with UDP-[3H] galactose and ovalbumin as substrate, and GT-II was assayed by selectively removing GT-II from serum by immunoabsorption with immobilized monoclonal antibody 3872, followed by assay of bound GT activity. GT was not specific for cancer, but GT-II was positive in 74% of the ovarian cancer patients, and remarkably high serum levels were observed in mesonephroid cancers, indicating its possible usefulness as a new tumor marker. Immunohistochemical staining revealed that GT-II was localized on the cell surface and in the cytoplasm, suggesting its production by tumor cells.
检测了妇科恶性肿瘤患者血清中半乳糖基转移酶（GT）及其同工酶（GT-II）的水平，GT-II可将尿苷二磷酸半乳糖中的半乳糖转移至N-乙酰葡糖胺等物质。以尿苷二磷酸-[3H]半乳糖和卵清蛋白为底物检测GT活性，通过用固定化单克隆抗体3872进行免疫吸附从血清中选择性去除GT-II，然后检测结合的GT活性来检测GT-II。GT并非癌症特异性指标，但74%的卵巢癌患者GT-II呈阳性，在中肾样癌患者中观察到血清水平显著升高，表明其可能作为一种新的肿瘤标志物。免疫组织化学染色显示GT-II定位于细胞表面和细胞质中，提示其由肿瘤细胞产生。
Zotero 插件